Last updated on March 2019

A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)


Brief description of study

This is a 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to compare the efficacy and safety of 2 dose regimens of TEV-48125 (Fremanezumab) versus placebo in adult patients for the prevention of ECH.

Clinical Study Identifier: NCT02945046

Contact Investigators or Research Sites near you

Start Over

Teva Investigational Site 13811

Santa Monica, CA United States
  Connect »

Teva Investigational Site 13814

Colorado Springs, CO United States
  Connect »

Teva Investigational Site 13810

Gainesville, FL United States
  Connect »

Teva Investigational Site 13829

Ormond Beach, FL United States
  Connect »

Teva Investigational Site 13830

Saint Petersburg, FL United States
  Connect »

Teva Investigational Site 13827

Albuquerque, NM United States
  Connect »

Teva Investigational Site 13824

Philadelphia, PA United States
  Connect »

Teva Investigational Site 13822

Virginia Beach, VA United States
  Connect »

Teva Investigational Site 32661

Konigstein im Taunus, Germany
  Connect »

Teva Investigational Site 13819

Canoga Park, CA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.